Filing Details
- Accession Number:
- 0001209191-23-002417
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-06 17:26:38
- Reporting Period:
- 2023-01-04
- Accepted Time:
- 2023-01-06 17:26:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1652130 | Intellia Therapeutics Inc. | NTLA | In Vitro & In Vivo Diagnostic Substances (2835) | 364785571 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1810882 | David Lebwohl | C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139 | Evp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-01-04 | 2,574 | $37.21 | 25,687 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
Billionaire Hedge Funds
